First AD

Second AD

Exciting Data and Trials in Progress from ASCO 2024

Please briefly discuss recent findings from ongoing trials and novel treatment strategies.

STELLAR-001 single-agent zanzalintinib biomarker analysis (Pal et al, ASCO 2024)

KEYNOTE-426 Phase 3 pembro + axitinib biomarker analysis (Rini et al., ASCO 2024 Abstract 4505)

Phase 3 trial len + pembro + belzutifan/quavonlima (Choueiri, ASCO GU 2022: Abstract TPS399)

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma

Peer Exchange

Elizabeth Wulff-Burchfield, MD, facilitates a conversation about several clinical trials, such as STELLAR-001 and KEYNOTE-426, which investigate various treatment approaches for renal cell carcinoma (RCC). 